CytomX Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
CTMX$1.98-9.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| December 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $38,052 | $17,171 |
| Short-term investments | 62,571 | 157,338 |
| Accounts receivable | 3,103 | 3,432 |
| Prepaid expenses and other current assets | 3,579 | 4,995 |
| Total current assets | 107,305 | 182,936 |
| Property and equipment, net | 2,467 | 3,958 |
| Intangible assets, net | 583 | 729 |
| Goodwill | 949 | 949 |
| Restricted cash | 1,027 | 917 |
| Operating lease right-of-use asset | 8,136 | 12,220 |
| Other assets | 66 | 83 |
| Total assets | $120,533 | $201,792 |
| Liabilities and Stockholders' Deficit | ||
| Current liabilities: | ||
| Accounts payable | $1,088 | $1,458 |
| Accrued liabilities | 12,338 | 17,599 |
| Operating lease liabilities - short term | 5,145 | 4,589 |
| Deferred revenues, current portion | 67,201 | 132,267 |
| Total current liabilities | 85,772 | 155,913 |
| Deferred revenue, net of current portion | 26,862 | 80,048 |
| Operating lease liabilities - long term | 4,240 | 9,385 |
| Other long-term liabilities | 4,115 | 3,893 |
| Total liabilities | 120,989 | 249,239 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' deficit | ||
| Convertible preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued and outstanding | — | — |
| Common stock, $0.00001 par value; 300,000,000 and 150,000,000 shares authorized, and 80,099,889 and 67,310,838 shares issued and outstanding at December 31, 2024 and 2023, respectively | 1 | 1 |
| Additional paid-in capital | 691,095 | 675,905 |
| Accumulated other comprehensive income | 27 | 95 |
| Accumulated deficit | (691,579) | (723,448) |
| Total stockholders' deficit | (456) | (47,447) |
| Total liabilities and stockholders' deficit | $120,533 | $201,792 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.